7 0 VOLUME 24 NUMBER 1 JANUARY 2017 nature structural & molecular biology a r t i c l e s fraction of hVKOR carries a Cys51-Cys132 disulfide. Because the active site Cys132 is located at the ER luminal surface 14, 15 , the presence of this disulfide bond affirms the luminal location of Cys51, as seen in the four-TM structure (Fig. 1) . Remarkably, warfarin selectively inhibits the Cys51-Cys132 form of hVKOR, stabilizing a putative warfarin-binding pocket 12 surrounded by known WRs 2, [22] [23] [24] [25] [26] . In support of this prediction, alanine-scanning mutagenesis identified novel WRs clustering around the pocket, and WRs directly contacting warfarin showed the strongest resistance. This accommodating pocket is formed during electron transfer, and the corresponding conformational state of hVKOR is chosen by warfarin to achieve effective inhibition.
RESULTS

A majority of cellular hVKOR carries a Cys51-Cys132 disulfide
The conflicting conclusions of the three-TM 14, [16] [17] [18] and four-TM 29, 30 models arise from topology analyses that have used modified variants of hVKOR, thus strongly suggesting that the native conformation can be perturbed by these modifications 31, 32 . Here, we probed the native topology of hVKOR on the basis of the redox status of cysteines in this oxidoreductase. Because stable disulfide bonds are formed in the ER but not in the cytosol 33 , the subcellular location of each cysteine can be revealed by its redox status. In particular, the location of Cys43 and Cys51 in either the cytosol or the ER is a major feature distinguishing the three-and four-TM models (Fig. 1) .
We monitored the redox status of cysteines through an MS-based in-cell footprinting method using isotope-coded N-ethylmaleimide 34 (NEM; Fig. 2a and Supplementary Note). Briefly, hVKOR cysteines in reduced form were in-cell labeled with NEM, which readily permeates the plasma and ER membranes. Subsequently, those cysteines forming disulfide bonds, which were not labeled by NEM, were reduced and then labeled with NEM-d 5 . Thus, the relative fraction of the NEM-d 5 label on a cysteine indicated the oxidation level.
We found that ~90% of Cys51 and Cys132, and 40% of Cys43 and Cys135, were oxidized in the cellular environment (Fig. 2b) . In contrast, three nonconserved 35 and nonessential 36, 37 cysteines in hVKOR-Cys16, Cys85 and Cys96-were found mostly in a reduced state; these cysteines should not form disulfide bonds, because in both topology models they are either in the cytosol or buried in the ER membrane (Fig. 1) . To confirm that a high fraction of conserved cysteines were oxidized because those cysteines form disulfides (Supplementary Note), we prereduced the cells with dithiothreitol (DTT) and observed that only the four conserved cysteines were significantly shifted to the reduced form, whereas there was no change for the three nonconserved cysteines (Fig. 2b) . We also observed that these disulfides were intramolecular bonds, because hVKOR was monomeric 5 in a nonreducing gel (Supplementary Fig. 1a ). All four conserved cysteines were capable of forming disulfide bonds, thus indicating that all are located in the relatively oxidizing environment of the ER lumen, as in the four-TM model (Fig. 1) .
Because Cys51 and Cys132 were predominantly oxidized (Fig. 2b) , the species with a Cys51-Cys132 disulfide represents a major cellular form of hVKOR. Indeed, through accurate mass measurements and MS/MS sequencing, we found that Cys51 and Cys132 were disulfide linked in peptides of various lengths, including those containing all conserved cysteines (Fig. 2c,d and Supplementary Fig. 1b,c) . We confirmed these Cys51-Cys132 disulfide bonds by identifying specific individual peptides after reduction (Fig. 2c) . In addition, we made a C43A C135A double mutant to eliminate interference from other possible disulfides, and we found that the Cys51-Cys132 disulfide was preserved (Supplementary Fig. 1d,e) . Given that the active site Cys132 is located at the luminal surface 14, 15 , the existence of the Cys51-Cys132 bond necessarily places Cys51 in the ER lumen, a result consistent with the four-TM conformation of hVKOR (Fig. 1) .
Disulfide exchange among conserved cysteines indicates electron transfer in cellular hVKOR
The proposed mechanism by which electron transfer maintains hVKOR activity 12 requires disulfide exchange among the four conserved cysteines, with Cys51-Cys132 as an intermediate state (Supplementary Fig. 2a) . Our crystallography studies of the bacterial homolog 12, 28 have shown that mutation of the conserved cysteines that are essential for electron transfer modifies the disulfide-bond pattern of the remaining cysteines in a predictable manner ( Supplementary  Fig. 2b ). In the present study, through in-cell MS-based quantification, we observed similar redox changes (Fig. 3a) in hVKOR peptides containing either a cysteine pair (Fig. 3b) or a single cysteine (Fig. 3c) . The most pronounced changes occurred when the major disulfide, Cys51-Cys132, was disrupted. Mutation of C132A or C51A converted the Cys43 Cys51 or Cys132 Cys135 pair, respectively, from a mixture of reduced and oxidized states to a mainly oxidized state (Fig. 3b) ; this result indicates that each cysteine of this disulfide can form an alternative disulfide when its normal partner is absent. For example, the mutation C132A induced the formation of Cys43-Cys51 disulfide, and the mutation C51A induced the formation of Cys132-Cys135 disulfide (Fig. 3a) . Formation of these disulfides can also be inferred from the oxidation states of peptides containing a single cysteine. The C132A mutation increased the oxidation of Cys43, whereas Cys51 remained highly oxidized (Fig. 3c) , a result consistent with the formation of a Cys43-Cys51 disulfide (Fig. 3a) . Similarly, the C51A mutation increased the oxidation level of Cys135, whereas Cys132 remained oxidized, a result consistent with the formation of a Cys132-Cys135 disulfide. These redox shifts, and a predictable pattern of shifts observed for other cysteine mutants ( Supplementary  Fig. 3 and Supplementary Note), support a catalytic mechanism involving electron transfer among the four conserved cysteines in hVKOR.
We also tracked electron transfer during hVKOR catalysis by monitoring redox-state changes induced by substrates. Treating the cells with an excess of the KO substrate shifted Cys43 Cys51 and Cys132 Cys135 pairs to a predominantly oxidized state, thus indicating the progressive formation of two disulfide bonds, Cys43-Cys51 and 4-TM  3-TM   TM1 TM4  TM3  TM1 TM4  TM3  TM2  TM2   16  85   96   16   85 Electron transfer ? Figure 1 Alternative models of hVKOR architecture to explain warfarin interaction and electron transfer. Left, four-TM model. Cys43, Cys51, Cys132 and Cys135 are oxidized (orange and pink colors indicate oxidation levels in Fig. 2b ) at the ER-luminal side. Interactions among these four conserved cysteines permit electron transfer (blue arrows). Right, three-TM model. Cys43 and Cys51 are reduced (green) at the cytosolic side and separated from Cys132 and Cys135, and therefore cannot mediate electron transfer.
a r t i c l e s Cys132-Cys135 (Fig. 4a,b) . Moreover, in peptides containing a single cysteine, the proportion of oxidized Cys43 and Cys135 was significantly increased, whereas Cys51 and Cys132 remained oxidized (Fig. 4c) .
We observed a similar effect with vitamin K (Fig. 4d,e) , another hVKOR substrate 5, 11 . In contrast, the three nonconserved cysteinesCys16, Cys85 and Cys96-were unaffected (Fig. 4c,e) . This oxidation pattern is expected because substrate reduction is coupled to cysteine oxidation in formation of the Cys132-Cys135 disulfide at the active site and is followed by a subsequent disulfide exchange generating the Cys43-Cys51 disulfide (Supplementary Fig. 2a ). When these conserved cysteines were mutated, substrate-induced oxidation was blocked for cysteines downstream ( Supplementary Fig. 4 ), because the electron-transfer pathway was hindered. In contrast, electron transfer was not affected by mutations of the three nonconserved cysteines ( Supplementary Fig. 4 ). Together, our results suggest that the redox shifts induced by substrates indicate a dynamic process of electron transfer among conserved cysteines in hVKOR.
Warfarin selectively inhibits hVKOR with the Cys51-Cys132 disulfide Establishing these redox changes during hVKOR catalysis is essential to understanding warfarin interactions, because in vitro studies have suggested that warfarin preferentially inhibits oxidized VKOR 21 .
Taking those findings as a starting point, we studied the effects of hVKOR redox states on warfarin binding in a cellular environment. We found that binding of warfarin and other vitamin K antagonists inhibited the alkylation of hVKOR by NEM, as determined through MS quantification ( Supplementary Fig. 5a and Supplementary Note) and also readily detected as a change in electrophoretic mobility (Fig. 5a) . Notably, we found that reducing cells with DTT hindered warfarin binding to hVKOR, and the order in which DTT and warfarin were added produced different results: when DTT was added first, warfarin did not bind to hVKOR, but when DTT was added after warfarin, the warfarin binding was less affected (Fig. 5b) . DTT hinders warfarin binding by disrupting one or more disulfide bonds. In contrast, the presence of disulfide bonds in hVKOR is required for warfarin binding and inhibition, both in vitro 21 and in cells.
To identify which disulfide bond is important for warfarin binding, we mutated cysteines to alanine or serine, and found that Cys51 and Cys132 mutations abolished warfarin binding ( Fig. 5c and Supplementary Figs. 5b and 6a) . We also found that C135A, but not C135S, impaired warfarin binding (Fig. 5c) , thus suggesting that a hydrogen bond involving Cys135 promotes warfarin binding. In fact, when a Cys51-Cys132 disulfide bond is formed, Cys135 is left unpaired with a free sulfhydryl group (wild-type hVKOR in Fig. 3a ) a r t i c l e s available for hydrogen bonding. We confirmed this redox pattern required by warfarin binding by comparing the double mutants C43A C135A and C43A C135S, in which the interference from Cys43 was eliminated (Fig. 5c) . Therefore, warfarin binds a specific redox state of hVKOR with a Cys51-Cys132 disulfide and a reduced Cys135 sulfhydryl, both of which are located at the active site. Binding to this redox state was further supported by the effects of cysteine mutations on the sensitivity of hVKOR activity to inhibition by warfarin. In particular, the C51A mutant was strongly resistant to warfarin (Fig. 5d) , whereas C132A and C135A were catalytically inactive ( Supplementary Fig. 6b ). Thus, disruption of the Cys51-Cys132 disulfide hinders warfarin inhibition. Together, these data show that warfarin, a potent anticoagulant, achieves effective inhibition by selectively binding to a major cellular form of hVKOR that contains a Cys51-Cys132 disulfide.
The binding orientation of warfarin
To understand the topology of warfarin binding to the Cys51-Cys132 state of hVKOR, we compared warfarin with 4-hydroxycoumarin (4HC), which lacks the phenyl butanone side group of the warfarin structure (Fig. 6a) . Although 4HC completely inhibited hVKOR at a high concentration, it did not induce the gel shift characteristic of warfarin binding (Fig. 6b) . Clearly, without the side group of warfarin, 4HC cannot maintain certain interactions with hVKOR that a r t i c l e s influence alkylation by NEM. We used MS to quantify the effects of 4HC and warfarin on susceptibility to NEM (Fig. 6c) . Compared with no treatment, 4HC treatment affected the alkylation of Cys43 on HL1-2 and Cys135 at the active site. In contrast, warfarin affected two additional cysteines, Cys16 on TM1 and Cys85 on TM2. This difference shows that the additional side group of warfarin interacts with the TMs and suggests that its 4HC moiety orients toward the active site and HL1-2. This binding orientation of warfarin is consistent with the locations of WRs, which are distributed in the TMs and in HL1-2 (refs. 12,28). WRs in HL1-2 induced more resistance to 4HC than to warfarin, whereas WRs on TM1 and TM4 preferentially conferred resistance to warfarin (Fig. 6d) . This trend supports the conclusion that the 4HC and phenyl butanone side group of warfarin interact primarily with HL1-2 and the TMs of hVKOR, respectively.
Novel WR mutations support predictions from MD simulation
To understand how warfarin interacts with VKOR in greater structural detail, we created a structural model of hVKOR that is based on a bacterial homolog (PDB 4NV5) 28 containing the disulfide corresponding to Cys51-Cys132 (Supplementary Fig. 2b) . We initially positioned warfarin in contact with the strong WR residues and ran a 200-ns molecular dynamics (MD) simulation that reached a local equilibrium. The simulation revealed a warfarin-binding pocket that is stabilized by Cys51-Cys132 and is surrounded by the naturally occurring WRs 2,22-26 ( Fig. 7a-c) .
Through alanine-mutagenesis scans of nearly the entire protein, we identified many novel WRs (Supplementary Fig. 7a ) that coincided remarkably well with the proposed region of warfarin binding (Fig. 7a-c and Supplementary Video 1) . The newly identified WRs, predicted by the MD model to directly contact warfarin (for example, F55A and N80A), were also highly resistant (Fig. 7a) , and mutations on HL1-2 and TMs conferred more resistance to 4HC and warfarin, respectively (Fig. 7d) . Contrary to the general trend, C51A on HL1-2 imparted more resistance to warfarin, probably because loss of the Cys51-Cys132 disulfide disrupted the warfarin-binding pocket and had less of an effect on the binding of 4HC because 4HC binds primarily to HL1-2 (Fig. 7e) .
DISCUSSION
With the novel MS-based footprinting method, we were able to monitor the native status of each cysteine in cellular hVKOR. The MS quantification provides direct evidence for the electron-transfer pathway. Moreover, the analysis of disulfide bonds in hVKOR effectively resolves the debate about its folding topology 14, [16] [17] [18] 29, 30 . In addition, establishing the catalytic process and architecture of hVKOR provides a basis for understanding interactions with warfarin.
The conflicting three-or four-TM models derived from previous studies suggest that the native conformation of hVKOR is sensitive to perturbation, such as truncations of TM domains 14 or fusions with large reporter proteins 16, 30 . In general, caution should be taken when analyzing proteins with a flexible structure 31, 38, 39 , and this example reinforces that notion. Furthermore, in many previous studies, measurements of the enzymatic activities of modified hVKOR constructs have not been reported together with topology analyses. In contrast, here we probed the active hVKOR without any truncation or large tag. In this native state, the four conserved cysteines in hVKOR form disulfide bonds in the oxidative ER lumen instead of being reduced in cytosol 33 . In particular, the Cys51-Cys132 disulfide linkage to the luminal active site indicates the luminal location of a Cys51-containing loop, thereby supporting the four-TM model (Fig. 1) .
The electron-transfer mechanism was proposed on the basis of studies of the bacterial VKOR homolog, which have suggested that the conserved Cys43 and Cys51 mediate the transfer in hVKOR 12 .
In vitro VKOR activity can be stimulated by reduced thioredoxin 40, 41 , a cytosolic protein that can function as an artificial partner 42 to transfer electrons. If Cys43 or Cys51 is mutated, thioredoxin cannot maintain hVKOR activity in microsomes 13 . However, in cellular assays, Cys51 mutation does not substantially affect the hVKOR activity 11, 16 ( Supplementary Fig. 6b) , thus raising the question of whether Cys43 and Cys51 mediate electron transfer in vivo.
To address this question, we tracked the cellular interaction of cysteines on the basis of their redox-state changes during catalysis, which are characteristic of the electron-transfer mechanism. After adding the substrates to cells (Fig. 4) , we observed progressive oxidation of Cys132-Cys135 and Cys43-Cys51 pairs through catalysis at the active site and subsequent electron transfer, respectively; in contrast, mutations of these conserved cysteines blocked the progressive oxidation ( Supplementary Fig. 4 ). In the absence of substrates, these mutations also changed the redox pattern ( Fig. 3 and Supplementary Fig. 3) , a r t i c l e s because breakage of the existing disulfides led to the formation of new disulfides; all these disulfides are essentially electron-transfer intermediates (Supplementary Fig. 2a) . The intriguing results of C51A mutation can be explained by invoking an additional pathway that also reduces the active site cysteines of hVKOR. Although the relative contribution of this alternative pathway remains unknown, our MS data clarify that electron transfer mediated by Cys43 and Cys51 indeed occurs in a cellular environment. One challenge of warfarin therapy is the high variation in effective doses as a result of genetic differences among patients, including those carrying resistance mutations. The MD model of the warfarinbinding pocket (Fig. 7c) is highly predictive of the location of these mutations (Fig. 7a) , both for the novel WRs identified by alanine scanning (Supplementary Fig. 7a ) and for previously known naturally occurring WRs. Among the strong new WRs, N80A is located on TM2, where no WR has previously been identified; F55A is on HL1-2, thus suggesting that this region maintains critical interactions with warfarin; Y25A (TM1), L120A and L124A (TM3) may interact with the side group of warfarin (Fig. 7d) ; C51A is resistant because the Cys51-Cys132 disulfide is required for warfarin binding. The new WR residues showing strong resistance are highly conserved in eukaryotic VKOR homologs (Supplementary Fig. 7b) . Therefore, these residues should form part of a conserved pocket that binds warfarin. Together, the locations of these residues and their interactions with warfarin provide a unified explanation for warfarin resistance: the naturally occurring and novel WR residues are clustered at the luminal side (Fig. 7a) , where they maintain the warfarin-binding pocket (Fig. 7c  and Supplementary Video 1) .
The selective binding of warfarin to the Cys51-Cys132 form of hVKOR explains the puzzling results in which the concentrations of warfarin required to inhibit the enzyme in vitro 2,27,43 are ~100-foldhigher than the effective concentrations in cell-based assays 11, 44 or estimates from clinical warfarin dosages 22, 27 . These in vitro studies are based on an assay that initiates hVKOR catalysis by reduction with DTT 45 , which provides electrons to the active site but bypasses 12 the normal electron-transfer pathway. In addition, as seen in our in-cell results (Fig. 5b) , in vitro prereduction with DTT makes hVKOR more resistant to warfarin 21 . In both settings, the reduction of all disulfides by DTT disrupts the Cys51-Cys132 disulfide that is required for optimal warfarin binding. Therefore, warfarin treatment before or after DTT reduction of hVKOR in vitro results in substantially different levels of inhibition, but the inhibition is always less than the hVKOR a r t i c l e s inhibition in intact cells, in which a major fraction of hVKOR exists in the oxidized Cys51-Cys132 state (Fig. 2b) .
Selective inhibition of the Cys51-Cys132 state by warfarin can be explained by conformational changes in hVKOR during electron transfer. Our molecular model of hVKOR, validated by novel WRs, is based on the crystal structures of the bacterial homolog 12, 28 , which have been determined for three different electron-transfer states. Our modeling template was the Cys51-Cys132 state, whereas previous modeling of warfarin binding 27 , performed when this selective inhibition and the orientation of warfarin binding were unknown (Figs. 5  and 6 ), has used a structure of the bacterial homolog captured in a different state. Comparison of these states in the bacterial structures reveals large conformational changes in the highly flexible HL1-2 region, which contains a short amphipathic helix that forms a cap over the active site. Part of this helix undergoes a winding and unwinding motion that facilitates electron transfer to the active site. The sequence of this flexible helix is highly conserved between the bacterial homolog and hVKOR 12, 35 ; therefore, both bacterial and human proteins may use a similar structural mechanism. As an intermediate state in the electron transfer (Supplementary Fig. 2a) , formation of the Cys51-Cys132 disulfide in hVKOR probably lowers the flexibility of HL1-2 and forces a longer segment of the conserved sequence to become α-helical 28 , thereby altering the conformation of the active site ( Supplementary Fig. 2b and Supplementary Video 2) . In the MD model of hVKOR, a specific conformation around the active site, stabilized by Cys51-Cys132, provides a fitting and closed pocket for warfarin binding (Fig. 7c and Supplementary Video 1) . In contrast, warfarin is essentially a conformation-specific inhibitor of hVKOR in this Cys51-Cys132 state.
Finally, our findings, which come after more than six decades of warfarin use, should enable the design of safer anticoagulants or more warfarin antidotes that can reverse the hemorrhage events caused by overdose. Such new drugs may be designed to target specific redox and conformational states of hVKOR, with the goals of preventing warfarin side effects and improving treatments for thrombotic and cardiovascular diseases.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. (Fig. 6d) , although C51A (red) on HL1-2 deviates from this general trend. The calculation of relative normalized resistance and s.e.m. is based on inhibition curves, as described in detail in Online Methods. Source data for resistance and basal activity are available in Supplementary Data Sets 3 and 4. (e) Cartoon explaining the response of the C51A mutant. Left, in wild-type hVKOR, the putative sites that bind the 4HC (orange) and side groups (green) of warfarin are located on HL1-2 and the TM region, respectively. Right, C51A (gray) breaks the Cys51-Cys132 disulfide, thus resulting in flexible movements that dissociate HL1-2 from the TMs. Because HL1-2 binds the 4HC group, this separation weakens warfarin binding but has less of an effect on the 4HC compound. Therefore, the C51A mutant shows more resistance to warfarin than to 4HC. POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.
ONLINE METHODS
Cell lines. The VKORC1 (hVKOR) and VKORC1L1 (hVKOR-like) double-knockout cells containing a chimeric gene encoding FIXgla-Protein C 11 , derived from the HEK293 cell line, was a gift from D.W. Stafford and J. Tie. The T-REx-293 cells 46 , derived from HEK293 and used for constructing stable cell lines, were a gift from S. Wanrooij. Cells were not tested for mycoplasma contamination.
Sample preparation for MS quantification of the apparent oxidized fraction of cysteines. Stable cell lines were established in 293TRex cells to express wildtype and mutant hVKOR proteins. Cells were grown on 15-cm plates, and each MS sample required an amount of cells from approximately five plates. The cells were washed once with ice-cold PBS. Subsequently, 1.8 mL labeling buffer 47, 48 was added to each plate; the buffer contained 20 mM NEM, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, and a protease-inhibitor cocktail (Roche). The plates were left on ice for 20 min with frequent shaking to facilitate the reaction of NEM with free cysteines. The cell lysate was collected into a new tube, and 200 µL of 1 M DTT (final concentration 100 mM) was added to quench the NEM reaction. This mixture was centrifuged at 4 °C for 15 min at 12,000g. The supernatant was loaded on a G-25 desalting column to remove DTT and NEM. The wild-type or mutant hVKOR proteins, each with a flag tag and ER-retention sequence, were immunopurified with anti-Flag M2 resin (Sigma), precipitated by trichloroacetic acid and subjected to reducing SDS-PAGE. The protein band of hVKOR was excised and reduced in gel with 5 mM Tris-(2-carboxyethyl)phosphine (TCEP) for 30 min at 56 °C, and the cysteines not labeled by NEM were subsequently modified with 10 mM NEM-d 5 isotope for 60 min at room temperature. The labeled protein was subjected to in-gel protease digestion (described below).
Sample preparation for MS detection of disulfide-bonded peptides.
To maintain intact disulfide bonds, cells were treated with NEM as described above, but without DTT quenching. Extra NEM was removed from the cell lysate with a G-25 desalting column. Subsequently, the hVKOR protein was immunopurified and subjected to nonreducing SDS-PAGE, and the hVKOR band was in-gel digested. After digestion, the peptide solutions were split, and one aliquot was reduced with TCEP to separate disulfide-linked peptides. The extracted ion chromatograms of the reduced and corresponding disulfide-linked peptides (i.e., untreated) were compared.
In-gel digestion. A previously described protocol 49 was modified to reach high sequence coverage that identified all seven cysteines of membrane-bound hVKOR. Briefly, gel pieces were digested overnight at 37 °C with 0.02 µg/mL chymotrypsin (Roche) in a buffer containing 50 mM Tris-HCl, pH 8.0, 10 mM CaCl 2 , and 0.1% RapiGest SF surfactant (Waters). The digestion reaction was terminated by treatment with formic acid for 30 min at 37 °C, and the peptides released from the in-gel digestion were directly used for MS analysis.
LC-MS/MS
analysis. An Eksigent 2D nanoLC system (Eksigent Technologies) and a Thermo LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) were used for LC-MS/MS analysis of the chymotryptic peptides. The parameters were modified from those described previously 50 . Briefly, the peptides were loaded onto a trap column (Acclaim PepMap100, 100 µm × 2 cm, C18, 5 µm, 100 Å, Thermo Scientific Dionex) at a flow rate of 4.5 µL/min with 0.1% formic acid in water. Subsequently, the peptides were separated on a reversed-phase column (0.0075 mm × 180 mm) packed in house with Michrom Magic C18 material (5-µm particle size and 200-Å pore size). An LC gradient of solvent B (0.1% formic acid in acetonitrile) was delivered at a flow rate of 260 nL/min for 0-10% in 5 min and 10-40% in 95 min. Mass spectra (m/z range 350-2,000) of the eluted peptides were acquired at high-mass-resolving power (50,000 for ions of m/z 400). The seven most abundant ions were selected for fragmentation by collisioninduced dissociation in the linear ion trap without charge-state rejection.
Criteria for selecting cysteine-containing peptides for the analysis of the apparent oxidized fraction. The LC-MS/MS raw data files were converted and searched with the MASCOT search engine against a custom-built database containing wild-type and mutant hVKOR sequences. NEM-cysteine, deuterated-NEMcysteine and oxidized methionine were selected in custom-built modification profiles. The chymotrypsin digestion generated peptide fragments of variable lengths containing the same cysteine(s), and these peptides were confirmed by the pairwise appearance of NEM-and NEM-d 5 -labeled species at the same LC retention time. Among the peptides identified by MASCOT, product-ion spectra were manually validated, thus affording six peptides for Cys16; three peptides each for Cys43, Cys51, Cys96, the Cys43 Cys51 pair and the Cys132 Cys135 pair; and one peptide each for Cys85, Cys132 and Cys135. The accurate m/z ratios of all charge states of these peptides (with NEM and NEM-d 5 modifications) were consistent with the assignments, as listed in Supplementary Data Set 1.
Calculation and statistics of the apparent oxidized fraction and percentage of redox states. An ion chromatogram was extracted for each peptide m/z ratio, and the peak area was measured with Xcalibur Qualbrowser. For peptides containing one cysteine, the apparent oxidized fraction was calculated by division of the peak area of the NEM-d 5 -modified peptide by the summed peak areas of NEM and NEM-d 5 modified peptides (i.e., the apparent oxidation fraction = NEMd 5 /(NEM-d 5 + NEM)). For peptides containing two cysteines, the percentage of each redox state (both cysteines oxidized, both reduced, or one reduced and one oxidized) was obtained by dividing the peak area of a given state by the summed peak areas of the three states.
The calculations were conducted for all the validated peptides (described above) containing the same cysteine(s). Peptides from three repeats of completely separate experiments (from sample preparation to MS analysis) were averaged together to yield the final values. Therefore, the mean and s.e.m. are from the combination of 18 peptides (6 peptides × 3 replicates) for Cys16; 9 peptides (3 peptides × 3 replicates) each for Cys43, Cys51, Cys96, the Cys43 Cys51 pair and the Cys132 Cys135 pair; and 3 peptides (1 peptide × 3 replicates) each for Cys85, Cys132 and Cys135. Two-tailed Student's t test was used, with P <0.01 as the significance threshold.
Identification of disulfide-bond-linked peptides. Disulfide-bond-linked peptides were analyzed with xQuest software 51 , as reported previously for cross-linked peptides 50 . The MASCOT search results for the nonreduced and TCEP-treated hVKOR samples were also compared: peptides containing free cysteines were identified only in the TCEP-treated samples, but not in the nonreduced samples. On the basis of the identification of peptides containing free cysteines, disulfidebonded peptides were identified and validated by manual examination of the product-ion data. An hVKOR peptide (VLGQDSILN) containing no cysteine was used as an internal standard to compare the peak intensities.
Gel-shift assay. Cells expressing wild-type hVKOR and mutants were grown in six-well plates and incubated with warfarin or 4HC for 24 h. The cells were washed once with ice-cold PBS and 120 µL of labeling buffer (20 mM NEM, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100 and a proteaseinhibitor cocktail; as above) was added to each well. The plates were left on ice with shaking for 20 min, and the cell lysates were transferred to a tube. The NEM labeling was quenched by addition of 1 M DTT to a 100 mM final concentration. After samples were centrifuged at 12,000g 4 °C for 15 min, the supernatant was subjected to SDS-PAGE under reducing conditions and subsequent western blotting with an anti-flag M2 antibody (Sigma, F3165).
Cell-based activity assay and statistics. VKOR activity assays were performed as previously described 11 . Briefly, hVKOR constructs were cloned into a pBudCE4.1 vector carrying a Metridia luciferase-encoding gene. The plasmids were transfected into VKORC1 (hVKOR) and VKORC1L1 (hVKOR-like) double-knockout cells containing a chimeric gene encoding FIXgla-Protein C. The carboxylation level of secreted FIXgla-PC was measured through ELISA by using the cell culture medium, and luciferase activity served as the control for transfection efficiency. To measure the IC 50 values of warfarin and 4HC, hVKOR-transfected cells were treated with warfarin or 4HC at 11 different concentrations. These inhibited activities were normalized to the activity of untreated cells. The IC 50 and s.e.m. values were obtained from inhibition curves with Prism 5 software.
Comparison of resistance of hVKOR mutants to warfarin and 4HC. The normalized warfarin resistance (nR war ) of hVKOR mutants was obtained as follows. First, the IC 50 values of wild-type and mutant hVKORs to warfarin were measured with cell-based activity assays (described above) in the same set of experiments. Next, the IC 50 values of the mutants were normalized to the IC 50 of wild-type hVKOR. The normalized 4HC resistance (nR 4HC ) of hVKOR mutants was obtained through the same approach. The relative normalized resistance of mutants to 4HC and to warfarin was given by the ratio of either nR 4HC /nR war if nR 4HC > nR war , or by nR war /nR 4HC if nR war > nR 4HC . All error propagations were calculated accordingly.
MD simulation. The initial homology model of hVKOR was generated with I-TASSER 52 by using the bacterial VKOR structure constrained with a disulfide corresponding to Cys51-Cys132 (PDB 4NV5) as a starting point. The warfarin molecule was docked, with the 4HC group facing HL1-2 and the side group facing the TMs, into the hVKOR homology model in Swissdock 53 . The longer HL1-2 loop in hVKOR was manually adjusted to place strong, naturally occurring WRs in contact with warfarin. The resulting hVKOR-warfarin complex was inserted into a pure POPC membrane bilayer with the CHARMM-GUI online tool 54 . To simulate the ER membrane, we used a surface area of 68.3 Å 2 per lipid for the POPC bilayer. The MD of the hVKOR-warfarin-membrane system was conducted with the GROMACS 4.6.7 package 55 and the Charmm36 force field. The force-field parameters for warfarin were generated with ParamChem on the basis of the Charmm FF 54 . The system was energy minimized with a steepest descent algorithm with a 0.01-nm step size and a 1.2-nm neighbor-list cutoff distance for Coulomb and Van der Waals interactions until the maximum force on any atom in the system fell below 1,000 kJ/mol/nm. The system was then equilibrated for 2.5 ns with a 0.001-fs time step and a Berendsen thermostat to hold the system temperature at 310.15 K. A Verlet cutoff scheme was used for the neighbor list. Particle mesh Ewald was used for the Coulomb interactions. The 200-ns production run was conducted with the Parrinello-Rahman barostat and velocity-rescaling thermostat. LINCS was used for bond restraints. Model coordinates and validation report are available in Supplementary Data Sets 5 and 6.
Data availability. All MS data that support the findings of this study have been deposited in the ProteomeXchange Consortium under accession code PXD003774. Supplementary Data Sets for Figures 2b, 3b,c, 4b-e, 5d, 6b-d  and 7a,d, and Supplementary Figures 1d, 3a, 4 , 5, 6b and 7a are available with the paper online. All other relevant data are available from the corresponding author on request.
